News from rxi pharmaceuticals corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 07, 2017, 07:05 ET RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 23, 2017, 07:05 ET RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 22, 2017, 07:05 ET PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology

PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on...


May 11, 2017, 07:05 ET RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 04, 2017, 07:02 ET RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 02, 2017, 07:02 ET RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


May 01, 2017, 07:02 ET RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global Health Impact Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Apr 25, 2017, 07:02 ET RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Apr 20, 2017, 07:02 ET RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Apr 18, 2017, 07:02 ET RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 31, 2017, 07:02 ET RXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 30, 2017, 07:02 ET RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 28, 2017, 07:02 ET RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 22, 2017, 07:02 ET RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 21, 2017, 07:02 ET RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Mar 16, 2017, 07:02 ET RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March 30, 2017

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Feb 14, 2017, 06:02 ET RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Feb 08, 2017, 06:02 ET RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Feb 07, 2017, 06:02 ET RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Jan 09, 2017, 07:02 ET RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet...


Dec 26, 2016, 07:02 ET RXi Pharmaceuticals to Present at the 9th Annual Biotech Showcase™

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


Dec 21, 2016, 09:53 ET RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public Offering and Full Exercise of Over-allotment Option

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


Dec 16, 2016, 08:15 ET RXi Pharmaceuticals Announces Pricing of $10 Million Underwritten Public Offering

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


Dec 13, 2016, 07:02 ET RXi Pharmaceuticals Provides Year End Update on its Business Development and Clinical Programs

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...


Nov 10, 2016, 07:02 ET RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical...